Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Raymond H Henderson"'
Publikováno v:
Cancer Research. 82:P5-14
INTRODUCTION An increasing body of evidence demonstrates that the COVID-19 pandemic of 2020 saw large reductions in the number of US patients being diagnosed with a variety of conditions, including cancer. A previous real world evidence study based u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab9290cb65e15006827958e8289d7224
https://doi.org/10.1158/1538-7445.sabcs21-p5-14-04
https://doi.org/10.1158/1538-7445.sabcs21-p5-14-04
Autor:
Raymond H. Henderson, Declan French, Ethna McFerran, Richard Adams, Harpreet Wasan, Robert Glynne-Jones, David Fisher, Susan Richman, Philip D. Dunne, Lisa Wilde, Timothy S. Maughan, Richard Sullivan, Mark Lawler
Publikováno v:
Henderson, R H, French, D, McFerran, E, Adams, R, Wasan, H, Robert Glynne-Jones, R, Fisher, D, Richman, S, Dunne, P D, Wilde, L, Maughan, T, Sullivan, R & Lawler, M 2022, ' Spend less to achieve more: economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer ', Journal of Cancer Policy, vol. 33, 100342 . https://doi.org/10.1016/j.jcpo.2022.100342
BACKGROUNDIn 2014, the COIN-B clinical trial demonstrated that intermittent cetuximab (IC) was a safe alternative to continuous cetuximab (CC), with less cytotoxic chemotherapy, in first-line treatment for KRAS wild-type metastatic colorectal cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8ff0da5da7d270c0916f9522032605d
https://doi.org/10.1016/j.jcpo.2022.100342
https://doi.org/10.1016/j.jcpo.2022.100342